Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CDK12 |
Variant | dec exp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | CDK12 dec exp indicates decreased expression of the Cdk12 protein. However, the mechanism causing the decreased expression is unspecified. |
Associated Drug Resistance | |
Category Variants Paths |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDK12 dec exp | ovarian cancer | sensitive | Melphalan | Preclinical | Actionable | In a preclinical study, the depletion of CDK12 in an ovarian cancer cell line by siRNAs resulted in the depletion of BRCA1 and sensitized the cells to the cross-linking agents Alkeran (melphalan), Platinol (cisplatin), and the PARP inhibitor veliparib (ABT-888) (PMID: 24554720). | 24554720 |
CDK12 dec exp | ovarian cancer | sensitive | Cisplatin | Preclinical | Actionable | In a preclinical study, the depletion of CDK12 in an ovarian cancer cell line by siRNAs resulted in the depletion of BRCA1 and sensitized the cells to the cross-linking agents Alkeran (melphalan), Platinol (cisplatin), and the PARP inhibitor veliparib (ABT-888) (PMID: 24554720). | 24554720 |
CDK12 dec exp | ovarian cancer | sensitive | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, the depletion of CDK12 in an ovarian cancer cell line by siRNAs resulted in the depletion of BRCA1 and sensitized the cells to the cross-linking agents Alkeran (melphalan), Platinol (cisplatin), and the PARP inhibitor, Veliparib (ABT-888) (PMID: 24554720). | 24554720 |
CDK12 dec exp | ovarian cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of ovarian cancer cell lines with decreased CDK12 expression in culture (PMID: 39321214). | 39321214 |
CDK12 dec exp | colon cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of a colon cancer cell line with decreased CDK12 expression in culture (PMID: 39321214). | 39321214 |
CDK12 dec exp | breast cancer | sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of a breast cancer cell line with decreased CDK12 expression in culture (PMID: 39321214). | 39321214 |